Eriksson S A, Lindgren J U
Karolinska Institute, Department of Orthopaedic Surgery, Huddinge University Hospital, Sweden.
Calcif Tissue Int. 1993 Jul;53(1):26-8. doi: 10.1007/BF01352011.
Twenty-two middle-aged women with severe osteoporosis were treated for 2 years with either 0.5 mg of synthetic human calcitonin subcutaneously three times per week combined with 0.5 micrograms of calcitriol and 0.5 g of calcium per day orally or calcium only. The treatment with calcitonin plus calcitriol (12 patients) resulted in a significantly increased calcium absorption rate. The mean values for serum phosphate did not change during the treatment period and the mean values did not differ between the treatment groups, but the serum calcium and urinary Ca/Cr ratio increased somewhat in the group given the combined treatment. There was no evidence that the combined treatment improved the bone density in this study. It is possible that calcitriol, instead of increasing the effect of calcitonin by suppression of the parathyroid, might have counteracted its effect by increasing the bone resorption.
22名患有严重骨质疏松症的中年女性接受了为期2年的治疗，其中12名患者每周皮下注射0.5毫克合成人降钙素3次，同时每天口服0.5微克骨化三醇和0.5克钙，另外10名患者仅口服钙。降钙素加骨化三醇治疗组（12名患者）的钙吸收率显著提高。治疗期间血清磷酸盐的平均值没有变化，且治疗组之间的平均值没有差异，但联合治疗组的血清钙和尿钙/肌酐比值有所增加。在本研究中，没有证据表明联合治疗能改善骨密度。骨化三醇可能不是通过抑制甲状旁腺来增强降钙素的作用，而是可能通过增加骨吸收来抵消其作用。
